杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2020/11/05 | 1,960 | 1,987 | 1,951 | 1,985 | +40 | +2.1% | 189,300 |
2020/11/04 | 1,915 | 1,946 | 1,892 | 1,945 | +14 | +0.7% | 178,500 |
2020/11/02 | 1,907 | 1,936 | 1,904 | 1,931 | +42 | +2.2% | 138,800 |
2020/10/30 | 1,899 | 1,900 | 1,880 | 1,889 | -21 | -1.1% | 124,000 |
2020/10/29 | 1,900 | 1,917 | 1,892 | 1,910 | -12 | -0.6% | 93,400 |
2020/10/28 | 1,920 | 1,929 | 1,902 | 1,922 | -9 | -0.5% | 96,000 |
2020/10/27 | 1,928 | 1,934 | 1,911 | 1,931 | -11 | -0.6% | 113,700 |
2020/10/26 | 1,960 | 1,976 | 1,939 | 1,942 | -14 | -0.7% | 95,000 |
2020/10/23 | 1,961 | 1,968 | 1,944 | 1,956 | +2 | +0.1% | 120,700 |
2020/10/22 | 1,968 | 1,968 | 1,945 | 1,954 | -27 | -1.4% | 114,400 |
2020/10/21 | 1,974 | 1,998 | 1,967 | 1,981 | -3 | -0.2% | 133,800 |
2020/10/20 | 2,010 | 2,012 | 1,979 | 1,984 | -30 | -1.5% | 176,900 |
2020/10/19 | 2,019 | 2,034 | 2,012 | 2,014 | -3 | -0.1% | 119,100 |
2020/10/16 | 2,043 | 2,046 | 2,012 | 2,017 | -31 | -1.5% | 108,800 |
2020/10/15 | 2,065 | 2,075 | 2,045 | 2,048 | -17 | -0.8% | 63,400 |
2020/10/14 | 2,100 | 2,107 | 2,061 | 2,065 | -53 | -2.5% | 98,300 |
2020/10/13 | 2,115 | 2,129 | 2,104 | 2,118 | -3 | -0.1% | 76,700 |
2020/10/12 | 2,137 | 2,142 | 2,108 | 2,121 | -11 | -0.5% | 88,400 |
2020/10/09 | 2,138 | 2,138 | 2,109 | 2,132 | -1 | ±0% | 106,400 |
2020/10/08 | 2,170 | 2,170 | 2,132 | 2,133 | -27 | -1.3% | 125,500 |
2020/10/07 | 2,164 | 2,174 | 2,155 | 2,160 | -4 | -0.2% | 99,100 |
2020/10/06 | 2,181 | 2,187 | 2,147 | 2,164 | -7 | -0.3% | 122,000 |
2020/10/05 | 2,143 | 2,194 | 2,143 | 2,171 | +46 | +2.2% | 114,700 |
2020/10/02 | 2,144 | 2,156 | 2,101 | 2,125 | - | - | 206,600 |
2020/10/01 | 0 | 0 | 0 | 0 | - | - | 0 |
2020/09/30 | 2,139 | 2,171 | 2,131 | 2,132 | -15 | -0.7% | 164,700 |
2020/09/29 | 2,126 | 2,160 | 2,108 | 2,147 | -43 | -2% | 125,000 |
2020/09/28 | 2,164 | 2,195 | 2,146 | 2,190 | +55 | +2.6% | 252,200 |
2020/09/25 | 2,157 | 2,180 | 2,131 | 2,135 | -41 | -1.9% | 216,200 |
2020/09/24 | 2,202 | 2,202 | 2,172 | 2,176 | -25 | -1.1% | 154,400 |
2020/09/23 | 2,210 | 2,218 | 2,189 | 2,201 | -24 | -1.1% | 166,000 |
2020/09/18 | 2,214 | 2,234 | 2,198 | 2,225 | +14 | +0.6% | 204,300 |
2020/09/17 | 2,182 | 2,211 | 2,168 | 2,211 | +24 | +1.1% | 110,400 |
2020/09/16 | 2,180 | 2,205 | 2,167 | 2,187 | +15 | +0.7% | 172,800 |
2020/09/15 | 2,164 | 2,174 | 2,151 | 2,172 | +10 | +0.5% | 108,400 |
2020/09/14 | 2,162 | 2,168 | 2,147 | 2,162 | +8 | +0.4% | 110,600 |
2020/09/11 | 2,143 | 2,159 | 2,131 | 2,154 | +31 | +1.5% | 154,700 |
2020/09/10 | 2,110 | 2,128 | 2,102 | 2,123 | +19 | +0.9% | 155,900 |
2020/09/09 | 2,062 | 2,108 | 2,060 | 2,104 | -4 | -0.2% | 205,600 |
2020/09/08 | 2,067 | 2,108 | 2,063 | 2,108 | +47 | +2.3% | 173,300 |
2020/09/07 | 2,036 | 2,076 | 2,034 | 2,061 | +24 | +1.2% | 130,600 |
2020/09/04 | 2,019 | 2,046 | 2,007 | 2,037 | +1 | ±0% | 159,100 |
2020/09/03 | 2,046 | 2,062 | 2,029 | 2,036 | +11 | +0.5% | 201,600 |
2020/09/02 | 1,996 | 2,034 | 1,996 | 2,025 | +13 | +0.6% | 160,500 |
2020/09/01 | 2,007 | 2,020 | 1,989 | 2,012 | +5 | +0.2% | 140,000 |
2020/08/31 | 1,990 | 2,034 | 1,988 | 2,007 | +28 | +1.4% | 290,500 |
2020/08/28 | 1,990 | 2,029 | 1,966 | 1,979 | -5 | -0.3% | 231,300 |
2020/08/27 | 1,990 | 1,996 | 1,979 | 1,984 | -15 | -0.8% | 128,800 |
2020/08/26 | 1,981 | 2,006 | 1,971 | 1,999 | -8 | -0.4% | 132,300 |
2020/08/25 | 2,024 | 2,024 | 1,999 | 2,007 | -1 | ±0% | 132,900 |
1101~
1150
件表示中 / 3694件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 148,400円 | +8.8% | +99.9% | 3.50% | 9.48倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ジーエヌアイ | 236,900円 | +21.7% | +999.9% | 0.00% | 9.86倍 | 3.26倍 |
|
中国の特発性肺線維症で高シェア、肺線維症後続薬進出。米国で人工骨も。米中に研究開発機能 |
持田薬 | 309,000円 | +3.0% | +27.5% | 2.59% | 19.56倍 | 0.85倍 |
|
医薬中堅。高脂血症薬、降圧薬など循環器系得意。婦人科系にも強み。消化器系育成。化粧品も |
栄研化 | 223,700円 | +0.4% | -8.4% | 2.37% | 28.72倍 | 1.62倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
ネクセラファーマ | 86,500円 | +20.3% | - | 0.00% | 152.56倍 | 1.13倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
市場注目の銘柄
チャート関連のコラム